432 Correlative analyses of serum biomarkers and clinical outcomes in the phase 2 study of lenvatinib, everolimus, and the combination, in patients with metastatic renal cell carcinoma following 1 VEGF-targeted therapy. (September 2015) - Glen, H.; Hsieh, J.; Michaelson, M.D.; Kim, H.J.; Sachdev, P.; Kadowaki, T.; Funahashi, Y.; Larkin, J.; Motzer, R.